Fixed combination of amlodipine/indapamide-retard in the treatment of uncontrolled hypertension in subjects over 55 years old [Фиксированная комбинация амлодипина и индапамида-ретард в лечении неконтролируемой артериальной гипертонии у лиц старше 55 лет]

Objective. To evaluate the antihypertensive efficacy and safety of a fixed combination of amlodipine/indapamide-retard in patients with uncomplicated uncontrolled arterial hypertension (HTN) in the older age group. Design and methods. We included 40 patients (average age — 62 years, men — 20 %, mean HTN duration — 9 years) with uncomplicated uncontrolled HTN in an open, single-center study. Fixed-combination therapy with amlodipine/indapamide-retard (5/1,5 mg) once a day for 4 weeks were prescribed. After 4 weeks, in patients who did not reach the target blood pressure (BP), the dose increased from 5/1,5 to 10/1,5 mg. The follow-up period was 12 weeks. Results. The initial systolic BP (SBP) was 165 [148; 171] mm Hg, diastolic BP (DBP) — 96 [80; 102] mm Hg. After a 12-week therapy with a fixed combination of amlodipine/indapamide-retard, SBP decreased by 31 mm Hg, DBP — by 17 mm Hg. Target clinical BP (< 140/90 mm Hg in patients without diabetes mellitus (DM), < 140/85 mm Hg in patients with diabetes mellitus) was achieved in 93 % patients. Central SBP measured by applanation tonometry decreased by 16 mm Hg, DBP — 10 mmHg, pulse pressure — 6 mmHg. Prior to treatment, the median of carotid-femoral pulse wave velocity (cfPWV) was 11,1 [7,8; 14,5] m/sec. After 12 weeks there was a decrease in cfPWV to 8,9 [6,7; 12,6] m/sec (p < 0,05 in comparison with the baseline). Conclusions. Fixed combination of amlodipine/thiazide-like diuretic in patients with uncomplicated uncontrolled 1–2 degree HTN has a high antihypertensive efficacy, allowing achievement of target BP in 93 % patients after 12-week therapy, with a satisfactory safety profile and metabolic neutrality. We showed the ability of a combination of amlodipine/indapamide-retard to reduce central SBP, pulse pressure in the aorta, and cfPWV. © 2018 All-Russian Public Organization Antihypertensive League. All rights reserved.